Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at ...

Meeting to be held in Chicago on April 8 and in San Francisco on April 9 hosted by Oppenheimer. Don't Miss Our End of Quarter Offers: Discover ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...

Transthyretin Amyloidosis Treatment Market explores key drug advances, regulatory developments, and growth trends through 2035 ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...